7 completed, 1 recruiting, 1 terminated, 1 withdrawn. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Recruiting 1, Terminated 1, Withdrawn 1 |
Follow Malignancies: new trials by email Literature Review of Malignancies trials Research Report on Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg - Malignancies, Solid Malignant Tumor | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 14 | 2026-06-25 | 2026-08-11 |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies TAB006, Toripalimab - Previously Treated, Advanced, Malignancies | Phase 1 | Withdrawn | Shanghai Junshi Bioscience Co., Ltd. | 2022-03-15 | 2022-05-31 | |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies chemotherapy, venetoclax - Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1 | Completed | AbbVie | 143 | 2017-11-08 | 2023-05-22 |
| Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers REGN3767, cemiplimab - Malignancies | Phase 1 | Completed | Regeneron Pharmaceuticals | 333 | 2016-11-07 | 2024-05-01 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 PWT-143 - Malignancies | Phase 1 | Completed | MEI Pharma, Inc. | 35 | 2015-06-29 | 2017-08-29 |
| Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors Carfilzomib, Dexamethasone - Neoplasms, Malignancies | Phase 1 | Completed | Emory University | 22 | 2014-08-01 | 2017-02-07 |
| Study of PWT33597 Mesylate in Subjects With Advanced Malignancies PWT33597 mesylate - Malignancies | Phase 1 | Completed | Pathway Therapeutics, Inc. | 22 | 2011-06-01 | 2012-10-25 |
| Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies satraplatin and capecitabine - Malignancies | Phase 1 | Terminated | Agennix | 24 | 2006-05-01 | 2012-03-23 |
| Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma Aroplatin - Malignancies, B-Cell Lymphoma | Phase 1 | Completed | Agenus Inc. | 21 | 2006-03-01 | 2008-10-27 |
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) CS-1008 (humanized anti-DR5 antibody) - Malignancies, Lymphoma | Phase 1 | Completed | Daiichi Sankyo | 40 | 2007-09-11 |
Neoplasms (10) · Lymphoma, Non-Hodgkin (2) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Neuroblastoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Glandular and Epithelial (1)
Calcium Dobesilate (1) · Capecitabine (1) · Dexamethasone (1) · Drug Therapy (1) · Injections, Subcutaneous (1) · bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II) (1) · carfilzomib (1) · cemiplimab (1) · satraplatin (1) · tigatuzumab (1) · toripalimab (1) · venetoclax (1)
AbbVie (1) · Agennix (1) · Agenus Inc. (1) · Daiichi Sankyo (1) · Emory University (1) · Jecho Biopharmaceuticals Co., Ltd. (1) · MEI Pharma, Inc. (1) · Pathway Therapeutics, Inc. (1) · Regeneron Pharmaceuticals (1) · Shanghai Junshi Bioscience Co., Ltd. (1)
United States (7) · United Kingdom (3) · Australia (2) · Canada (1) · China (1) · France (1) · Germany (1) · Ireland (1) · Netherlands (1) · South Korea (1) · Switzerland (1)
Bradley C. Carthon, MD, PhD (1) · Pui Leung, MBChB (1) · Sheng Yao, PhD (1) · William Gradishar, MD (1)
PMID 29595064, PMID 30458930, PMID 34088831, PMID 38900987, PMID 39368878, PMID 39422598, PMID 40062648, PMID 40266036
2016 (1), 2017 (1)